The role of microglia and P2X7 receptors in gliomas

Liyen Katrina Kan, David Williams, Kate Drummond, Terence O'Brien, Mastura Monif

Research output: Contribution to journalReview ArticleResearchpeer-review

12 Citations (Scopus)


Gliomas are the most prevalent tumours of the central nervous system and present with high morbidity and mortality. The most common and most aggressive form of glioma is glioblastoma multiforme, of which patients have a median survival time of only 12 to 15 months. Current treatment options are limited and have a small impact on clinical outcome and prognosis. There is accumulating evidence that microglia, the immunocompetent cells of the central nervous system, and the purinergic P2X7 receptor (P2X7R) may contribute to tumour progression and pathology. Importantly, P2X7R on both tumour cells and infiltrating microglia is overexpressed in animal and human glioma cultures. Factors released by glioma cells and P2X7R activation recruit microglia into the largely immunosuppressive tumour microenvironment where they have been demonstrated to contribute to either tumour proliferation or tumour suppression. It is likely that P2X7R mediates a range of microglia effector functions in the glioma setting, potentially increasing tumour growth and proliferation. This review evaluates current evidence on the roles of microglia and P2X7R in glioma pathogenesis. Understanding the nature, mechanisms and outcomes of microglia and P2X7R activation in gliomas is necessary for the development of more therapies with increased efficacy and specificity.

Original languageEnglish
Pages (from-to)138-146
Number of pages9
JournalJournal of Neuroimmunology
Publication statusPublished - 15 Jul 2019


  • Brain tumour
  • Glioblastoma
  • Glioma
  • Microglia
  • P2X7 receptor
  • P2X7R

Cite this